CompletedNCT00524043
Low-dose extended-release paliperidone or placebo for schizophrenia
About this title
Read the official source — NCT00524043Researchers compared Paliperidone ER and placebo to find out how the approaches affected psychotic symptoms in people with schizophrenia.
Medication studyAges 18+Multiple countries
Understand this study
What did researchers investigate?
Researchers compared Paliperidone ER and placebo to find out how the approaches affected psychotic symptoms in people with schizophrenia.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: from 18 years. Other eligibility criteria applied.
- Listed locations
- Cerritos and 19 more locationsSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateSeptember 2007
- Recruitment status
- Completed
- Enrollment listed in the registry
- 201
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States, India, Taiwan
- Age range
- Over 18 Years
- Official registry ID
- NCT00524043
- Official title
Show the full official title
A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of a Fixed Dosage of 1.5 mg/Day of Paliperidone Extended Release (ER) in the Treatment of Subjects With Schizophrenia
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedCerritos, United States · Torrance, United States · Washington D.C., United States
17 more locations
- Bradenton, United States
- Leesburg, United States
- Atlanta, United States
- Rockville, United States
- Nutley, United States
- Cedarhurst, United States
- Hollis, United States
- Moore, United States
- Austin, United States
- Calicut, India
- Hyderabad, India
- Mumbai, India
- Pune, India
- Varanasi, India
- Hualien City, Taiwan
- Tainan, Taiwan
- Taipei, Taiwan
Questions about this study
What did researchers investigate?
Researchers compared Paliperidone ER and placebo to find out how the approaches affected psychotic symptoms in people with schizophrenia.
Who is behind this study?
The study sponsor is Johnson & Johnson Pharmaceutical Research & Development, L.L.C., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including Paliperidone ER and Placebo.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: from 18 years. Other eligibility criteria applied.
Want to explore more studies?
Explore studiesRelated studies
Paliperidone Injections Compared With Oral Medication for Schizophrenia
18F-Dihydroxyphenylalanine (DOPA) Positron Emission Tomography (PET) Study to Explore Dopamine Synthesis Capacity in the Whole Striatum After 2 Weeks of Treatment With Ralmitaront or Placebo in Participants With Schizophrenia